Biolife Solutions INC Form 4 insider transactions

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, sold 536 shares of common stock on July 7, 2025, as part of a pre-arranged 10b5-1 plan to cover tax withholding from restricted stock vesting.

BioLife Solutions' Chief Marketing Officer, Todd Berard, sold 304 shares of common stock to satisfy tax withholding obligations related to restricted stock vesting, as part of a pre-arranged 10b5-1 trading plan.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions Inc., sold 711 shares of common stock for $22.23 per share, as part of a pre-established Rule 10b5-1 trading plan.

Casdin Partners Master Fund, a 10% owner and director of BioLife Solutions Inc., reported the sale of 1,000,000 shares of common stock for $23.8 per share.

BioLife Solutions Chief Marketing Officer, Todd Berard, sold 362 shares of common stock for $23.7 per share to satisfy tax withholding obligations related to restricted stock vesting.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 637 shares of common stock for $23.70 per share to satisfy tax withholding obligations under a pre-existing Rule 10b5-1 trading plan.

BioLife Solutions Inc.'s Chief Financial Officer, Troy Wichterman, sold 1,042 shares of common stock for $23.7 per share to satisfy tax withholding obligations related to restricted stock vesting.

BioLife Solutions' Chief Technology Officer, Sean Werner, sold 65 shares of common stock for $23.70 per share on June 10, 2025, as part of a pre-arranged Rule 10b5-1 trading plan to satisfy tax withholding obligations.

BioLife Solutions' Chief Human Resources Officer, Sarah Aebersold, sold 235 shares of common stock for $23.7 per share to satisfy tax withholding obligations related to restricted stock vesting.

Karen A. Foster, Chief Quality and Operations at BioLife Solutions Inc., sold 320 shares of common stock for tax withholding purposes, as disclosed in a recent SEC Form 4 filing.

BIOLIFE SOLUTIONS' Chief Quality and Operations, Karen A. Foster, sold 251 shares of common stock for $22.46 per share to satisfy tax withholding obligations under a Rule 10b5-1 trading plan.

BioLife Solutions' Chief Human Resources Officer, Sarah Aebersold, sold 217 shares of common stock for $22.46 per share on May 28, 2025, to cover tax withholding obligations related to restricted stock vesting, as part of a pre-established 10b5-1 trading plan.

BioLife Solutions' Chief Marketing Officer, Todd Berard, sold 348 shares of common stock for $22.46 per share to satisfy tax withholding obligations related to restricted stock vesting.

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, reported the sale of 521 common shares to cover tax obligations and the acquisition of 45,269 restricted stock units.

BioLife Solutions' Chief Technology Officer, Sean Werner, sold 109 shares of common stock for $22.46 per share to satisfy tax withholding obligations related to restricted stock vesting.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 583 shares of common stock for $22.46 per share to satisfy tax withholding obligations, as part of a pre-existing Rule 10b5-1 trading plan.

Casdin Partners amends its previous Form 4 filing to reflect that it received cash instead of shares in BioLife Solutions Inc. following the acquisition of PanThera CryoSolutions, Inc.

Troy Wichterman, CFO of BioLife Solutions, sold 932 shares of common stock at $20.11 per share on April 9, 2025, to satisfy tax withholding obligations related to vesting restricted stock.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 569 shares of common stock on April 9, 2025, to cover tax withholding obligations related to vesting restricted stock.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 210 shares of common stock on April 9, 2025, to cover tax withholding obligations related to vesting restricted stock.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 324 shares of common stock on April 9, 2025, at a price of $20.11 per share to satisfy tax withholding obligations.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions Inc., sold 286 shares of common stock on April 9, 2025, to cover tax withholding obligations related to vesting restricted stock.

Casdin Partners acquired 27,994 shares of Biolife Solutions Inc. common stock as part of the acquisition of PanThera CryoSolutions by Biolife Solutions.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 5,771 shares of common stock on April 1, 2025, to cover tax withholding obligations related to vesting restricted stock.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 8,902 shares of common stock on April 1, 2025, to cover tax withholding obligations related to vesting restricted stock.

Troy Wichterman, CFO of BioLife Solutions, sold 25,687 shares of common stock on April 1, 2025, to cover tax withholding obligations related to vesting restricted stock.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, sold 7,869 shares of common stock on April 1, 2025, at a price of $22.66 per share to cover tax withholding obligations.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 10,589 shares of common stock on April 1, 2025, to cover tax withholding obligations.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, reports the acquisition of common stock through restricted stock grants.

Director Amy DuRoss reports selling shares of BioLife Solutions under a 10b5-1 trading plan and acquiring restricted stock.